Targets › PLAT
16 programs from 16 companies in 70 trials: 37 Phase 3, 21 Phase 2, 9 Phase 4, 3 Phase 1; Neurology, Cardiovascular, Respiratory; next expected readout Dec 2026.
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. (UniProt, P00750)
Open in Phaseline: the race on PLAT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| Amsterdam UMC | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 4 | Empyema, Pleural | Oct 2028 |
| Insel Gruppe AG, University Hospital Bern | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 4 | Ischemic Stroke | Jan 2029 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke | Dec 2026 |
| CSPC Mingfule Pharmaceutical (Guangzhou) | Tenecteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke; ST-segment Elevation Myocardial Infarction (STEMI); Ischemic Stroke; Stroke, Ischemic … | Sep 2027 |
| Boehringer Ingelheim | Tenecteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke | Oct 2027 |
| Assistance Publique - Hôpitaux de Paris | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Pulmonary Embolism | Mar 2028 |
| Jesper Kjaergaard | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Pulmonary Embolism | Jun 2028 |
| Central Hospital, Nancy, France | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Stroke, Acute Ischemic | Sep 2028 |
| King's College Hospital NHS Trust | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Eye Diseases | Dec 2028 |
| Guri Hagberg | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Stroke | Dec 2028 |
| 115 People's Hospital | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Stroke, Acute Ischemic | Dec 2028 |
| Yongjun Wang | Reteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Acute Ischemic Stroke | Mar 2029 |
| Copenhagen University Hospital, Rigshospitalet | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 3 | Pulmonary Embolism | – |
| South West Sydney Local Health District | Alteplase Tissue-type plasminogen activator exogenous protein | PLAT | Phase 2 | Acute Respiratory Failure | Dec 2026 |
| Children's National Research Institute | Aminocaproic Acid Plasminogen inhibitor; Tissue-type plasminogen activator inhibitor | PLG, PLAT | Phase 2 | Craniosynostosis | Jan 2028 |
Acute Ischemic Stroke (13) Ischemic Stroke (6) Stroke (5) Stroke, Acute Ischemic (4) Stroke, Ischemic (4) Pulmonary Embolism (3) Ischemic Stroke, Acute (2) Musculoskeletal Injury (2) Microscopic Colitis (2) Investigating the Importance of the Subjective Psychedelic Experience (2) ST-segment Elevation Myocardial Infarction (STEMI) (1) Minor Ischemic Stroke (1)
protein or peptide (9), small molecule (6), mixed (1)
Insel Gruppe AG, University Hospital Bern (1) Guri Hagberg (1) Central Hospital, Nancy, France (1) CSPC Mingfule Pharmaceutical (Guangzhou) (1) King's College Hospital NHS Trust (1) South West Sydney Local Health District (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Jesper Kjaergaard (1) University of Calgary (1) Amsterdam UMC (1) Boehringer Ingelheim (1) Assistance Publique - Hôpitaux de Paris (1) 115 People's Hospital (1) Copenhagen University Hospital, Rigshospitalet (1) Yongjun Wang (1) Children's National Research Institute (1)
CNR1 (1) IL12B (1) IL23A (1) ADRB2 (1) HTR2A (1) NR3C1 (1) TNF (1) PTGS2 (1) PTGS1 (1) PLG (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.